Transcode Therapeutics, Inc. 8-K

What Happened

• TransCode Therapeutics, Inc. (RNAZ) filed an 8‑K announcing its 2026 Annual Meeting of Stockholders will be held on July 2, 2026. The company set the record date for voting at the meeting as the close of business on May 28, 2026.
• Because the 2026 meeting date differs by more than 30 days from the 2025 Annual Meeting (held August 29, 2025), the company is notifying stockholders of adjusted submission deadlines under Rule 14a‑5(f) of the Exchange Act.

Key Details

• Meeting date: July 2, 2026; Record date: May 28, 2026.
• Deadline to submit proposals for inclusion in the proxy (Rule 14a‑8) and to provide notice for director nominations or other business (per the Bylaws): 5:00 p.m. Eastern / close of business on June 11, 2026.
• Mail/submission address for proposals and notices: Corporate Secretary, TransCode Therapeutics, 6 Liberty Square, #2382, Boston, MA 02109.
• Stockholders who intend to solicit proxies for director nominees other than the company’s nominees must provide the information required by Rule 14a‑19 by the close of business on June 11, 2026.

Why It Matters

• Investors who want to submit proposals, nominate directors, or run competing proxy solicitations must meet the specified June 11, 2026 deadlines and follow SEC rules (Rule 14a‑8 and Rule 14a‑19) and Delaware law; late submissions will not be included in proxy materials or considered at the meeting.
• The filing clarifies timing and procedural requirements ahead of the meeting so stockholders know how and when to participate in corporate governance decisions.